查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1986870

降血脂药物市场规模、份额、趋势和预测：按药物类别、给药途径、分销管道和地区划分，2026-2034 年

Antihyperlipidemic Drugs Market Size, Share, Trends and Forecast by Drug Class, Route of Administration, Distribution Channel, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3个工作天内

价格

2025年全球抗高血脂症药物市场规模为136亿美元。展望未来，IMARC集团预测，该市场将在2026年至2034年间以3.78%的复合年增长率成长，到2034年达到192亿美元。目前，北美市场是主要驱动力，预计2025年将占据超过32.7%的市场。北美市场成长的主要驱动因素包括高血脂症和心血管疾病的高发生率、人口老化、肥胖、久坐的生活方式以及不健康的饮食习惯。此外，强大的研发投入、先进的医疗基础设施、政府倡议、他汀类药物、PCSK9抑制剂和新型降脂药物的日益普及以及医保覆盖范围的扩大，都进一步推动了降血脂药物市场份额的增长。

推动该市场成长的因素包括高血脂症和心血管疾病的日益流行，这两种疾病仍然是全球主要的死亡原因。老化、肥胖和久坐的生活方式会导致胆固醇水平升高，从而推高了对降血脂药物的需求。他汀类药物、贝特类药物、胆汁酸结合剂和PCSK9抑制剂的广泛应用，以及贝培多酸等新型治疗方法的出现，正在拓展治疗选择。政府所推行的胆固醇管理、预防保健和医疗保险报销政策等倡议，进一步促进了市场成长。药物传递技术的新方法，透过将治疗方法与个人化医疗策略相结合，正在改善治疗效果。不断提高的健康意识，加上保险覆盖范围的扩大和製药公司持续的研发投入，正在推动创新解决方案的涌现，这些解决方案正在发达市场和新兴市场蓬勃发展。

美国抗高血脂症药物市场仍然受到高血脂症、肥胖和心血管疾病高发生率的驱动，这些疾病仍然是发病率和死亡率的主要原因。根据《美国预防医学杂誌》（AJPM）报告，高血脂症在美国人群中十分常见。在美国，约有32.8%的成年男性和36.2%的成年女性的总胆固醇水平达到或超过200 mg/dL，或低密度脂蛋白胆固醇（LDL-C）水平达到或超过130 mg/dL。老化、缺乏运动和不良饮食习惯会导致胆固醇水平升高，从而增加对降血脂药物的需求。他汀类药物、PCSK9抑制剂和新型降脂疗法的广泛应用得益于完善的医疗保健基础设施、保险覆盖范围以及政府促进心血管健康的措施。美国食品药物管理局 (FDA)核准新的降血脂药物，持续增加对药物研发的投资，以及个人化医疗和生物製药疗法的推广，进一步加速了该国市场的成长。

降血脂药物市场趋势：

高血脂症和心血管疾病盛行率增加

高血脂症、肥胖和心血管疾病 (CVD) 发病率的上升是抗高血脂症药物市场的主要驱动因素。例如，非传染性疾病风险因子协作组织 (NCD-RisC) 发布的数据显示，到 2024 年，全球将有超过 10 亿人肥胖，其中包括约 8.8 亿成年人和 1.59 亿 5 至 19 岁的儿童和青少年。世界肥胖联盟分析的数据显示，约有 30 亿人超重或肥胖，而且地球上绝大多数人居住在超重或肥胖比体重过轻更容易造成健康风险的国家。不健康的饮食习惯、久坐的生活方式和遗传倾向会导致高胆固醇水平，从而推动了对降血脂药物的需求。心肌梗塞、中风和动脉粥状硬化是全球主要的死亡原因，迫使医疗专业人员开立他汀类药物、PCSK9 抑制剂和其他降血脂疗法。各国政府和医疗机构都在积极推广胆固醇管理项目，这进一步推动了市场成长。由于心血管疾病仍然是主要的公共卫生问题，因此对有效的长期胆固醇管理方案的需求持续上升。

降血脂疗法的进展与药物创新

降血脂药物的持续研发催生了多种新型药物，包括PCSK9抑制剂（依洛尤单抗、阿利西尤单抗）、贝培多酸以及联合治疗。儘管他汀类药物仍占据市场主导地位，但这些新治疗方法为对他汀类药物不耐受或血脂异常高风险的患者提供了新的治疗选择。基因疗法和生物製药也日益受到关注，它们在提高疗效和患者依从性方面发挥重要作用。 FDA对新药的核准以及探索下一代降脂药物的临床试验进一步加剧了市场竞争。製药公司正增加对精准医疗、人工智慧驱动的药物研发以及联合製剂的投资，以强化其胆固醇管理方案。例如，2025年2月，FDA核准了Ctexli（kenodiolus）用于治疗成人脑腱黄斑部病变（CTX）。 Ctexli是FDA核准的首个用于治疗CTX的药物，CTX是一种罕见的脂质贮积症候群。

政府主导的措施和医疗保险的扩大

政府主导的医疗保健计划和宣传宣传活动正在推动对降血脂药物的需求。许多国家正在製定胆固醇检测指南、报销政策和公共卫生倡议，以减轻心血管疾病（CVD）的负担。在北美和欧洲等地区，完善的保险覆盖范围和处方药计划使患者能够获得他汀类药物和先进的降血脂疗法。各国政府和监管机构，例如美国食品药物管理局（FDA）和欧洲药品管理局（EMA），正在持续核准成本效益的学名药，并鼓励进行心血管疾病预防方面的研究，这进一步提振了抗高血脂症药物市场的前景。例如，2024年11月，Esperion宣布大冢製药株式会社（Otsuka Pharmaceutical Co., Ltd.，简称大冢製药）已向日本厚生劳动省提交了新药认证高胆固醇症（NDA），拟在日本生产和销售贝培多酸，用于治疗高胆固醇血症和遗传性高胆固醇症。

目录

第一章：序言

第二章：调查方法

  • 调查目的
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章：引言

第五章：全球降血脂药物市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 市场区隔：依药物类别划分

  • 他汀类药物
  • 胆汁酸吸附剂
  • 胆固醇吸收抑制剂
  • 贝特类衍生物
  • PCSK9抑制剂
  • 同时用药
  • 其他的

第七章 市场区隔：依给药途径

  • 口服
  • 静脉注射

第八章 市场区隔：依分销通路划分

  • 医院药房
  • 零售店
  • 线上零售商

第九章 市场区隔：依地区划分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章 SWOT 分析

第十一章：价值链分析

第十二章：波特五力分析

第十三章：价格分析

第十四章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Amgen Inc.
    • AstraZeneca plc
    • Daiichi Sankyo Company Limited
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A5622

The global antihyperlipidemic drugs market size was valued at USD 13.6 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 19.2 Billion by 2034, exhibiting a CAGR of 3.78% during 2026-2034. North America currently dominates the market, holding a significant market share of over 32.7% in 2025. The market in North America is fueled by the high prevalence of hyperlipidemia and cardiovascular diseases, aging populations, obesity, sedentary lifestyles, and unhealthy diets. Strong R&D investments, advanced healthcare infrastructure, government initiatives, rising adoption of statins, PCSK9 inhibitors, and novel lipid-lowering drugs, along with insurance coverage, further fuel antihyperlipidemic drugs market share.

The market is driven by the rising prevalence of hyperlipidemia and cardiovascular diseases, which remain the leading causes of mortality globally. Aging populations, obesity, and sedentary lifestyles contribute to increased cholesterol levels, fueling demand for lipid-lowering medications. The widespread use of statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors, along with emerging therapies like bempedoic acid, is expanding treatment options. Government initiatives promoting cholesterol management, preventive healthcare, and reimbursement policies further support market growth. New approaches in drug delivery combine treatments and individual medical strategies to improve the results of treatments. Advanced healthcare awareness coupled with expanded insurance coverage and sustained research and development investments by pharmaceutical organizations promotes innovative solutions that drive the expansion of both developed and emerging economies markets.

The market for antihyperlipidemic drugs in the United States is driven by the high prevalence of hyperlipidemia, obesity, and cardiovascular diseases, which remain the leading causes of morbidity and mortality. According to the American Journal of Preventive Medicine (AJPM), hyperlipidemia is frequent among the American population. In the United States, approximately 32.8% of adult men and 36.2% of adult females had total cholesterol levels of >=200 mg/dL and low-density lipoprotein cholesterol levels of >=130 mg/dL. Aging populations, sedentary lifestyles, and poor dietary habits contribute to rising cholesterol levels, increasing the demand for lipid-lowering medications. The widespread adoption of statins, PCSK9 inhibitors, and novel lipid-lowering therapies is supported by strong healthcare infrastructure, insurance coverage, and government initiatives promoting cardiovascular health. The FDA's approval of new lipid-lowering drugs, continuous pharmaceutical R&D investments, and the expansion of personalized medicine and biologic therapies further accelerate market growth in the country.

ANTIHYPERLIPIDEMIC DRUGS MARKET TRENDS:

Rising Prevalence of Hyperlipidemia and Cardiovascular Diseases

The growing incidence of hyperlipidemia, obesity, and cardiovascular diseases (CVDs) is a primary driver of the antihyperlipidemic drugs market. For instance, in 2024, more than one billion people worldwide are estimated to be obese, including around 880 million adults and 159 million children and adolescents between the ages of 5 and 19, according to data released by the NCD Risk Factor Collaboration (NCD-RisC). According to data analyzed by the World Obesity Federation, around 3 billion people are overweight or obese and the majority of people on the planet reside in countries where being overweight or obese poses a greater health risk than being underweight. Unhealthy dietary habits, sedentary lifestyles, and genetic predisposition contribute to high cholesterol levels, increasing the demand for lipid-lowering drugs. Heart attacks, strokes, and atherosclerosis are leading causes of mortality worldwide, pushing healthcare providers to prescribe statins, PCSK9 inhibitors, and other lipid-lowering therapies. Governments and healthcare organizations are promoting cholesterol management programs, further fueling market growth. As CVDs remain a major public health concern, the demand for effective long-term cholesterol control solutions continues to rise.

Advancements in Lipid-Lowering Therapies and Drug Innovations

Continuous research and development (R&D) in antihyperlipidemic drugs has led to the development of novel drug classes such as PCSK9 inhibitors (evolocumab, alirocumab), bempedoic acid, and combination therapies. While statins dominate the market, newer therapies offer alternative treatment options for patients with statin intolerance or high-risk lipid profiles. Gene-based treatments and biologics are gaining traction, improving efficacy and patient compliance. FDA approvals for novel drugs and clinical trials exploring next-generation lipid-lowering agents are further driving competition. Pharmaceutical companies are investing in precision medicine, AI-driven drug discovery, and combination drug formulations to enhance cholesterol management solutions. For instance, in February 2025, the FDA authorized Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved medication for CTX, a rare lipid storage syndrome.

Government Initiatives and Expanding Healthcare Coverage

Government-led preventive healthcare programs and awareness campaigns are driving demand for lipid-lowering medications. Many countries have established cholesterol screening guidelines, reimbursement policies, and public health initiatives to reduce the burden of CVDs. In regions like North America and Europe, strong insurance coverage and prescription drug plans ensure patient access to statins and advanced lipid-lowering therapies. Governments and regulatory bodies such as the FDA and EMA continue to approve cost-effective generics and encourage research in cardiovascular disease prevention, further creating a positive antihyperlipidemic drugs market outlook. For instance, in November 2024, Esperion stated that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has filed a New Drug Application (NDA) with the Japanese Ministry of Health, Labour, and Welfare to manufacture and sell bempedoic acid in Japan for the treatment of hypercholesterolemia and familial hypercholesterolemia.

ANTIHYPERLIPIDEMIC DRUGS INDUSTRY SEGMENTATION:

Analysis by Drug Class:

  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others

Statins stand as the largest drug class in 2025, holding around 38.7% of the market due to their proven efficacy in lowering LDL cholesterol, reducing cardiovascular risks, and preventing heart attacks and strokes. They are the first-line therapy for hyperlipidemia and widely prescribed due to their cost-effectiveness, availability, and strong clinical backing. Statins like atorvastatin, rosuvastatin, and simvastatin dominate the market due to their long-term safety profile, widespread adoption, and inclusion in treatment guidelines. Additionally, expanding insurance coverage, generic drug availability, and increasing awareness of cholesterol management contribute to their dominance. Their role in primary and secondary prevention of cardiovascular diseases further solidifies their market leadership.

Analysis by Route of Administration:

  • Oral
  • Intravenous

Oral formulations hold a major share in the market due to their ease of administration, high patient compliance, and widespread availability. Statins, the most prescribed lipid-lowering drugs, are mostly taken orally, making them the dominant treatment option. Other oral drugs like ezetimibe, fibrates, and bile acid sequestrants further contribute to market share. The affordability of oral medications, combined with long-term cholesterol management needs and generic drug availability, strengthens their market presence in both developed and emerging economies.

Intravenous (IV) formulations are expected to hold a significant share due to the rising demand for PCSK9 inhibitors and advanced lipid-lowering therapies. Patients with severe hypercholesterolemia or statin intolerance often receive IV-administered monoclonal antibodies like evolocumab and alirocumab, which offer rapid and effective cholesterol reduction. Hospitals and specialty clinics prefer IV therapies for high-risk patients requiring immediate lipid control. Increased adoption of targeted biologics, ongoing clinical trials, and physician preference for hospital-administered treatments further drive the IV segment's market growth.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Stores
  • Online Retailers

Hospital pharmacies hold the major share in the antihyperlipidemic drugs market due to the high volume of prescriptions for cardiovascular disease management in hospitals. Patients with acute coronary syndromes , strokes, and other cardiovascular conditions often receive statins and other lipid-lowering therapies as part of hospital treatment and post-discharge care. Hospitals ensure consistent drug availability, immediate access to critical medications, and adherence to treatment protocols. Additionally, physician-directed prescriptions, better patient monitoring, and integration with insurance and reimbursement systems make hospital pharmacies a preferred distribution channel. The increasing number of cardiovascular procedures, routine lipid screenings, and inpatient care facilities further drive their dominance.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 32.7%. The market in North America is driven by the high prevalence of hyperlipidemia, obesity, and cardiovascular diseases, which are leading causes of mortality. The region has a well-established healthcare infrastructure, advanced lipid-lowering therapies, and strong R&D investments in drug development. Widespread adoption of statins, PCSK9 inhibitors, and novel therapies is supported by government initiatives, insurance coverage, and preventive healthcare programs. The aging population, sedentary lifestyles, and unhealthy dietary habits further fuel demand. Additionally, clinical advancements, FDA approvals for new lipid-lowering drugs, and strategic collaborations between pharmaceutical companies contribute to market expansion in the United States and Canada.

KEY REGIONAL TAKEAWAYS:

UNITED STATES ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

In 2025, the United States accounted for over 90.00% of the antihyperlipidemic drugs market in North America. The United States is witnessing a growing antihyperlipidemic drugs adoption due to growing investment in pharmaceutical sectors, driving the expansion of drug manufacturing and research. According to reports, in the US pharmaceutical industry, there were 25 private equity deals announced in Q3 2024, worth a total value of USD 2.3 Billion. With pharmaceutical sectors focusing on innovation, the demand for advanced antihyperlipidemic drugs continues to rise. Increasing financial support for pharmaceutical sectors enhances the development of novel therapies, facilitating wider accessibility and improved treatment options. The commitment of pharmaceutical sectors to technological advancements contributes to the efficiency of antihyperlipidemic drugs, ensuring better patient adherence. Expanding pharmaceutical sectors encourage collaborations and clinical trials, further strengthening the market. The focus on research in pharmaceutical sectors leads to the introduction of enhanced formulations, catering to the rising demand. Investments in pharmaceutical sectors support the establishment of specialized healthcare units, ensuring effective drug distribution. The rising competition within pharmaceutical sectors results in cost-effective solutions, increasing affordability. Pharmaceutical sectors' efforts to develop targeted therapies enhance the effectiveness of antihyperlipidemic drugs, promoting their adoption. As pharmaceutical sectors integrate digital tools, accessibility and distribution channels improve, ensuring a wider reach.

ASIA PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Asia-Pacific is experiencing a growing antihyperlipidemic drugs adoption due to growing cholesterol related disease, increasing the demand for effective lipid-lowering treatments. According to survey, 31% of Indians struggle with high cholesterol, with Kerala topping the list with an alarming 63% prevalence. Rising cholesterol related disease prevalence has intensified the focus on preventive healthcare, driving antihyperlipidemic drugs demand. Increased awareness of cholesterol related disease encourages early diagnosis, leading to higher prescription rates. Growing dietary and lifestyle changes contribute to cholesterol related disease, necessitating medical intervention. Healthcare initiatives addressing cholesterol related disease emphasize the need for long-term antihyperlipidemic drugs therapy. The healthcare sector is integrating screening programs to detect cholesterol related disease early, facilitating wider drug adoption. With urbanization influencing dietary habits, cholesterol related disease cases continue to surge, strengthening market growth. The expansion of healthcare networks supports the accessibility of antihyperlipidemic drugs, mitigating cholesterol related disease risks. Medical advancements in cholesterol related disease management improve treatment efficacy, reinforcing antihyperlipidemic drugs' role. As cholesterol related disease becomes a significant concern, governments and private institutions invest in research, fostering pharmaceutical innovation.

EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Europe is experiencing a growing antihyperlipidemic drugs adoption due to growing coronary artery disease (CAD) cases, necessitating effective treatment options. According to reports, in 2021 there were 1.71 Million deaths in the EU resulting from diseases of the circulatory system, which was equivalent to 32.4% of all deaths. The increasing burden of coronary artery disease drives demand for long-term lipid management solutions, boosting antihyperlipidemic drugs usage. Healthcare policies addressing coronary artery disease prioritize early intervention, expanding prescription rates. The growing aging population is more susceptible to coronary artery disease, elevating antihyperlipidemic drugs demand. With healthcare systems implementing preventive measures for coronary artery disease, regular cholesterol monitoring is increasing. Research and development targeting coronary artery disease enhance antihyperlipidemic drugs' effectiveness, strengthening market growth. The rise in sedentary lifestyles and dietary habits contributes to coronary artery disease, emphasizing pharmaceutical intervention. Pharmaceutical advancements in coronary artery disease management introduce improved formulations, ensuring better patient adherence. Healthcare institutions are expanding coronary artery disease awareness programs, promoting antihyperlipidemic drugs usage. Government initiatives tackling coronary artery disease support antihyperlipidemic drugs accessibility, ensuring widespread adoption.

LATIN AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Latin America is witnessing growing antihyperlipidemic drugs adoption due to growing online retailers. According to reports, the Latin America market currently boasts over 300 Million digital buyers. Expanding digital healthcare platforms are improving patient access to lipid-lowering medications, driving market penetration. The increasing convenience of online pharmacies is simplifying prescription fulfilment, encouraging higher adoption rates. Competitive pricing and discount offer on digital platforms are enhancing affordability, promoting sustained drug consumption. The rising presence of e-commerce in pharmaceutical distribution is streamlining product availability, ensuring widespread reach. The growing preference for digital healthcare solutions is strengthening consumer reliance on online pharmaceutical services, reinforcing antihyperlipidemic drug sales. Strengthening logistics networks are further improving drug delivery efficiency, boosting accessibility.

MIDDLE EAST AND AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET ANALYSIS

Middle East and Africa are experiencing growing antihyperlipidemic drugs adoption due to growing healthcare facilities. According to Dubai Healthcare City Authority report, Dubai's healthcare sector saw rapid growth, with 4,482 private medical facilities and 55,208 licensed professionals by 2022, projected to expand further by 3-6% in facilities and 10-15% in professionals in 2023. Expanding hospital networks and specialty clinics are improving patient access to lipid-lowering treatments, fuelling market growth. Increasing government investment in healthcare infrastructure is strengthening antihyperlipidemic drug availability, ensuring widespread distribution. The rising number of cardiology centers is driving greater prescription rates, bolstering demand. Growing medical advancements are facilitating early diagnosis and cholesterol management, encouraging sustained drug utilization. Expanding pharmaceutical supply chains are enhancing distribution efficiency, ensuring consistent access to antihyperlipidemic medications.

COMPETITIVE LANDSCAPE:

The market is highly competitive, with key players focusing on drug innovation, strategic partnerships, and regulatory approvals. Leading pharmaceutical companies such as Pfizer, Merck & Co., AstraZeneca, Novartis, Amgen, and Sanofi dominate the market through extensive R&D and strong global distribution networks. Statins remain the largest drug class, with atorvastatin and rosuvastatin widely prescribed. The emergence of PCSK9 inhibitors like evolocumab (Repatha) and alirocumab (Praluent) has intensified competition, offering alternatives for statin-intolerant patients. Patent expirations of branded statins have led to an influx of generic competition, lowering costs. Companies are also investing in novel lipid-lowering drugs, combination therapies, and biologics to maintain market leadership amid evolving healthcare regulations and reimbursement policies.

The report provides a comprehensive analysis of the competitive landscape in the antihyperlipidemic drugs market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • AstraZeneca plc
  • Daiichi Sankyo Company Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the antihyperlipidemic drugs market?

2. What is the future outlook of the antihyperlipidemic drugs market?

3. What are the key factors driving the antihyperlipidemic drugs market?

4. Which region accounts for the largest antihyperlipidemic drugs market share?

5. Which are the leading companies in the global antihyperlipidemic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antihyperlipidemic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Fibric Acid Derivatives
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 PCSK9 Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Combination
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Retailers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amgen Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Daiichi Sankyo Company Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Merck & Co. Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Novartis AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Pfizer Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Sanofi S.A
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials

List of Figures

  • Figure 1: Global: Antihyperlipidemic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Antihyperlipidemic Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antihyperlipidemic Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 5: Global: Antihyperlipidemic Drugs Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Antihyperlipidemic Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Antihyperlipidemic Drugs Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Antihyperlipidemic Drugs (Statins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Antihyperlipidemic Drugs (Statins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Antihyperlipidemic Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Antihyperlipidemic Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Antihyperlipidemic Drugs (Fibric Acid Derivatives) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Antihyperlipidemic Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Antihyperlipidemic Drugs (Combination) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Antihyperlipidemic Drugs (Combination) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Antihyperlipidemic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Antihyperlipidemic Drugs (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Antihyperlipidemic Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Antihyperlipidemic Drugs (Intravenous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Antihyperlipidemic Drugs (Intravenous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Antihyperlipidemic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Antihyperlipidemic Drugs (Retail Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Antihyperlipidemic Drugs (Retail Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Antihyperlipidemic Drugs (Online Retailers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Antihyperlipidemic Drugs (Online Retailers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: North America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: North America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: United States: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: United States: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Canada: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Canada: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Asia-Pacific: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Asia-Pacific: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: China: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: China: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Japan: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Japan: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: India: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: India: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: South Korea: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: South Korea: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Australia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Australia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Indonesia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Indonesia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Europe: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Europe: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Germany: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Germany: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: France: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: France: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: United Kingdom: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: United Kingdom: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Italy: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Italy: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Spain: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Spain: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Russia: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Russia: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Latin America: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Latin America: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Brazil: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Brazil: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Mexico: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Mexico: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Others: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Others: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Middle East and Africa: Antihyperlipidemic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Middle East and Africa: Antihyperlipidemic Drugs Market: Breakup by Country (in %), 2025
  • Figure 80: Middle East and Africa: Antihyperlipidemic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Global: Antihyperlipidemic Drugs Industry: SWOT Analysis
  • Figure 82: Global: Antihyperlipidemic Drugs Industry: Value Chain Analysis
  • Figure 83: Global: Antihyperlipidemic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antihyperlipidemic Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 3: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 4: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Antihyperlipidemic Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Antihyperlipidemic Drugs Market: Competitive Structure
  • Table 7: Global: Antihyperlipidemic Drugs Market: Key Players